Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | TTR | P02766 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3988831 | 1.00 | L3MBTL1 (0.45) | L3MBTL1TDP1HCAR2NPSR1CTDSP1 | |
| SCHEMBL12150587 | 1.00 | L3MBTL1 (0.45) | L3MBTL1TDP1HCAR2NPSR1CTDSP1 | |
| SCHEMBL4426142 | 1.00 | L3MBTL1 (0.45) | L3MBTL1TDP1HCAR2NPSR1CTDSP1 | |
| SCHEMBL3988833 | 1.00 | L3MBTL1 (0.45) | L3MBTL1TDP1HCAR2NPSR1CTDSP1 | |
| SCHEMBL4425298 | 1.00 | L3MBTL1 (0.45) | L3MBTL1TDP1HCAR2NPSR1CTDSP1 | |
| SCHEMBL1243883 | 1.00 | L3MBTL1 (0.45) | L3MBTL1TDP1HCAR2NPSR1CTDSP1 | |
| SCHEMBL9914107 | 1.00 | L3MBTL1 (0.45) | L3MBTL1TDP1HCAR2NPSR1CTDSP1 | |
| SCHEMBL3988829 | 1.00 | L3MBTL1 (0.45) | L3MBTL1TDP1HCAR2NPSR1CTDSP1 | |
| SCHEMBL15355842 | 0.85 | L3MBTL1 (0.43) | L3MBTL1TDP1HCAR2NPSR1CTDSP1 | |
| SCHEMBL9812980 | 0.84 | MAPT (0.38) | L3MBTL1MAPTCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3313847-A1 | PROCESS FOR THE PREPARATION OF [(1 S,2R)-3-[[(4-AMINOPHENYL)SULFONYL](2-METHYLPROPYL)AMINO]-2-HYDROXY-1 -(PHENYLMETHYL)PROPYL]-CARBAMIC ACID (3R,3AS,6AR)HEXAHYDRO FURO[2,3-B]FURAN-3-YL ESTER AND ITS AMORPHOUS FORM | MSN Laboratories Private Limited (IN) | 2018-05-02 | — | — | EP | claimed |
| WO-2016207907-A1 | PROCESS FOR THE PREPARATION OF [(1 S,2R)-3-[[(4-AMINOPHENYL)SULFONYL] (2-METHYLPROPYL)AMINO]-2-HYDROXY-1 -(PHENYLMETHYL)PROPYL]-CARBAMIC ACID (3R,3AS,6AR)HEXAHYDRO FURO[2,3-B]FURAN-3-YL ESTER AND ITS AMORPHOUS FORM | MSN LABORATORIES PRIVATE LIMITED (IN) | 2016-12-29 | — | — | WO | claimed |
| EP-3882246-A1 | MONOBACTAM COMPOUNDS AND USE THEREFOR | Nanjing Sanhome Pharmaceutical Co., Ltd. (CN) | 2021-09-22 | — | — | EP | disclosed |
| WO-2020098635-A1 | MONOBACTAM COMPOUNDS AND USE THEREFOR | 南京圣和药业股份有限公司 | 2020-05-22 | — | — | WO | disclosed |
| US-10633390-B2 | Process for the preparation of [(1S,2R)-3-[[(4-aminophenyl)sulfonyl] (2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-carbamic acid (3R,3AS,6AR)hexahydro furo [2,3-B]furan-3-YL ester and its amorphous form | MSN LABORATORIES PRIVATE LIMITED (IN) | 2020-04-28 | — | — | US | disclosed |
| EP-1732931-B1 | METHODS FOR THE PREPARATION OF (3R,3aS,6aR) HEXAHYDRO-FURO[2,3-b]FURAN-3-OL | JANSSEN SCIENCES IRELAND UC (IE) | 2016-05-18 | — | — | EP | disclosed |
| US-7595408-B2 | Methods for the preparation of (3R,3aS,6aR) hexahydro-furo[2,3-b]furan-3-ol | TIBOTEC PHARMACEUTICALS, LTD. (IE) | 2009-09-29 | — | — | US | disclosed |
| EP-1669353-B1 | Process for preparing alpha, beta - unsaturated esters | DAISO CO LTD (JP) | 2009-05-20 | — | — | EP | disclosed |
| US-20070208184-A1 | METHODS FOR THE PREPARATION OF (3R,3aS,6aR) HEXAHYDRO-FURO[2,3-b]FURAN-3-OL | Janssen Sciences Ireland Unlimited Company (IE) | 2007-09-06 | — | — | US | disclosed |
| EP-1732931-A1 | METHODS FOR THE PREPARATION OF (3R,3aS,6aR) HEXAHYDRO-FURO[2,3-b]FURAN-3-OL | Tibotec Pharmaceuticals Ltd. (IE) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005095410-A1 | METHODS FOR THE PREPARATION OF (3R,3aS,6aR) HEXAHYDRO-FURO[2,3-b]FURAN-3-OL | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10633390-B2 | Process for the preparation of [(1S,2R)-3-[[(4-aminophenyl)sulfonyl] (2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-carbamic acid (3R,3AS,6AR)hexahydro furo [2,3-B]furan-3-YL ester and its amorphous form | FFAR1, CYP2S1, CYP1B1 | L3MBTL1 4385/4885TDP1 1052/4885HCAR2 38/4885 |
| US-20070208184-A1 | METHODS FOR THE PREPARATION OF (3R,3aS,6aR) HEXAHYDRO-FURO[2,3-b]FURAN-3-OL | HTR3C, UGT1A3, HTR3D | L3MBTL1 4520/4885TDP1 4205/4885HCAR2 633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.